Helping older men with prostate cancer make decisions about surveillance
Official title: Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy Testing
Run by M.D. Anderson Cancer Center · NCT06785441 · Data updated 2026-11-12
This study tests a new educational tool to help older men with localized prostate cancer decide if they should keep or change their active surveillance plan.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years and up |
| Sex | Men only |
| Enrollment | 180 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | May 25, 2023 |
| Main results expected | February 2, 2027 |
| Study ends | February 2, 2030 |
| Registry record updated | February 4, 2025 |
| Trial ID | NCT06785441 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include males aged 65 or older who have localized prostate cancer and have not received curative treatment.
✕Probably not a fit
Patients currently undergoing treatment for another cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study tests the effectiveness of an educational tool designed to assist older men with localized prostate cancer in making informed decisions about whether to continue or reduce active surveillance. The intervention aims to facilitate shared decision-making between patients and healthcare providers regarding the need for ongoing surveillance testing. By evaluating different versions of this decision aid, the study seeks to gather preliminary data that could inform future comparative studies.
Why it matters
Potential benefit: If successful, this approach could empower patients to make more informed choices about their prostate cancer management, potentially reducing unnecessary procedures.
How similar studies have gone: Other studies have shown promise in using decision aids for cancer management, suggesting that this approach could be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: 1. Males aged 65 or older 2. Diagnosis of localized prostate cancer 3. Have not received curative intent treatment for their prostate cancer 4. Fluent in English Care partners/caregivers: 1. Aged 18 or older 2. Fluent in English 3. Involved with the care of an eligible patient (i.e. partner, close friend, family member, companion) Exclusion Criteria: Patients 1\. Currently receiving treatment for another cancer (primary or recurrence) Care partners/caregivers 1\. None
Where it's running
-
M.D. Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Lisa Lowenstein, MD — M.D. Anderson Cancer Center
- Study coordinator: Lisa Lowenstein, MD
- Email: deescalatepca@mdanderson.org
- Phone: 713-563-0020
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.